Objective:

To investigate the efficacy and safety of different adjuvant treatment regimens for patients with intrahepatic cholangiocarcinoma (ICC).

Approach:

Key Findings:

• Significant differences in RFS (p = 0.045) and OS (p = 0.0084) were observed between the CH group (GEMOX and capecitabine) and non-AT group.
• No significant differences in RFS (p = 0.73) or OS (p = 0.47) were found between capecitabine and GEMOX.
• The GEMOX group had a higher incidence of grade 3-4 adverse reactions (17.1%).
• No significant differences in RFS or OS were observed when comparing chemotherapy combined with immunotherapy to chemotherapy alone.
• Subgroup analysis indicated potential benefits of chemotherapy combined with immunotherapy for patients with CA19-9 >39 U/ml and ALP >100 U/L.

Interpretation:

Capecitabine showed a more favorable safety profile compared to GEMOX, but the addition of immunotherapy did not provide overall benefit.

Limitations:

• The study is retrospective and may be subject to selection bias.
• Findings need confirmation in larger studies.

Conclusion:

Capecitabine and GEMOX have similar prognostic outcomes, but capecitabine is safer.

Attribution Notice

This content is an AI-generated, fully rewritten summary based on a published scholarly article. It does not reproduce the original text and is not a substitute for the original publication. Readers are encouraged to consult the source for full context, data, and methodology.